Search Results

Category: Therapeutics


Return to Cornell Startups

AffyImmune Therapeutics

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018

Location: Natick, MA

Foundation Cornell Technology Licensed: 2017

Akelos, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.

Location: New York, New York

Foundation Cornell Technology Licensed: 2018

Angiocrine Bioscience, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Angiocrine Bioscience, Inc., is developing both research and therapeutic products using stem and endothelial cell related technologies.

Location: New York, NY

Foundation Cornell Technology Licensed: 2012

Aufbau Medical Innovations Ltd.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator: Center for Life Science Ventures

Aufbau Medical Innovations is an Irish Operating Company that develops novel therapeutics and diagnostics for ophthalmic diseases.

Location: Dublin, Ireland / Ithaca, NY

Foundation Cornell Technology Licensed: 2020

BlinkBio, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

BlinkBio, Inc. employs specialized Bioorthogonal chemistries for the delivery of next generation medicines for the treatment of cancer and other diseases. BlinkBio has optimized their proprietary chemistries into two types of novel linkers: one that allows the improved targeting of cytotoxic cancer medicines designed to rapidly kill cancer cells (so called Small Molecule Drug Conjugates (SMDCs) and Antibody Drug Conjugates (ADCs)); and the other that designs larger self-assembling therapeutics to target important cancer genes (such as MYC and p53) which exist inside cells and are not addressable using more traditional cancer therapeutics.

 

Location: Jupiter, FL

Foundation Cornell Technology Licensed: 2009

Convergent Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University.

 

Location: New York

Foundation Cornell Technology Licensed: 2021

Faeth Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Faeth Therapeutics, Inc. is a data-driven, evidence-based healthcare company, with a mission to rethink the role of nutrition in the fight against cancer.

Location: San Francisco, CA

Foundation Cornell Technology Licensed: 2020

Hemogenyx Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BM”) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.

Location: Buffalo, NY

Foundation Cornell Technology Licensed: 2014

IpiNovyx Bio Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune and inflammatory are treated through a reversable, ultra-potent and non-toxic approach.

Location: West Nyack, NY

Foundation Cornell Technology Licensed: 2021

Larkspur Biosciences, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Location: Boston, MA

Foundation Cornell Technology Licensed: 2021

LEXEO Therapeutics, LLC

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.

Location: New York, NY

Foundation Cornell Technology Licensed: 2020

Novita Pharmaceuticals, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.

Location: New York, NY

Foundation Cornell Technology Licensed: 2010

Ratio Therapeutics

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.

Location: New York, NY

Foundation Cornell Technology Licensed: 2021

Sedec Therapeutics, Inc.

Category: Therapeutics
Campus: Ithaca
Incubator:

Sedec is a therapeutics company that aims to inhibit key factors in a subset of CD4+ T cells to decrease inflammation. This approach can be used to treat T cell-mediated autoimmune disorders, such as inflammatory bowel disease.

Location: Boston, MA

Foundation Cornell Technology Licensed: 2021

Stealth BioTherapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Stealth BioTherapeutics, Inc., is a clinical stage, biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal and metabolic diseases. The company’s first clinical candidate, Bendaviaâ„¢, targets the mitochondria to treat cardio-renal and microvascular impairments.

Location: Newton, MA

Foundation Cornell Technology Licensed: 2006

Vernx Biotechnology Pty. Ltd.

Category: Therapeutics
Campus: Ithaca
Incubator:

Vernx Biotechnology is developing a range of nutrition products using branched fatty acids (BCFA) for multiple uses: to improve gastrointestinal health in pre-mature and non-premature infants, as a nutritional supplement for adults, and for eventual therapeutic use.

Location: New South Wales, Australia

Foundation Cornell Technology Licensed: 2016

Versatope Therapeutics, Inc.

Category: Therapeutics
Campus: Ithaca
Incubator:

Versatope Therapeutics is using exosomes (extracellular vesicles) derived from genetically engineered probiotics as a technology platform for the targeted delivery of large molecules used in vaccines, therapeutics and diagnostics. The company has worked with accelerators/incubators MassCONNECT, MassChallenge, and JLABS.

Location: Boston, MA

Foundation Cornell Technology Licensed: 2018

Volastra Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.  The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.

Location: New York, NY

Foundation Cornell Technology Licensed: 2019

XyloCor Therapeutics, Inc.

Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:

XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.

Location: New York, NY

Foundation Cornell Technology Licensed: 2015